Abstract
Acute Myeloid Leukemia (AML) is one of the most aggressive types of hematological neoplasm. To support the specialists’ decision about the appropriate therapy, patients with AML receive a prognostic of outcomes according to their cytogenetic and molecular characteristics, often divided into three risk categories: favorable, intermediate, and adverse. However, the current risk classification has known problems, such as the heterogeneity between patients of the same risk group and no clear definition of the intermediate risk category. Moreover, as most patients with AML receive an intermediate-risk classification, specialists often demand other tests and analyses, leading to delayed treatment and worsening of the patient’s clinical condition. This paper presents the data analysis and an explainable machine-learning model to support the decision about the most appropriate therapy protocol according to the patient’s survival prediction. In addition to the prediction model being explainable, the results obtained are promising and indicate that it is possible to use it to support the specialists’ decisions safely. Most importantly, the findings offered in this study have the potential to open new avenues of research toward better treatments and prognostic markers.
Supported by CAPES, CNPq, and FAPESP grant #2021/13325-1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
InterpretML is a Python library that provides a set of tools and algorithms for interpreting and explaining machine learning models. The documentation is available at https://interpret.ml/docs.
References
Arber, D.A., et al.: International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11), 1200–1228 (2022)
Caruana, R., et al.: Intelligible models for healthcare: predicting pneumonia risk and hospital 30-day readmission. In: Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, pp. 1721–1730. ACM, Sydney NSW Australia (2015)
Charrot, S., et al.: AML through the prism of molecular genetics. Br. J. Haematol. 188(1), 49–62 (2020)
Combi, C., et al.: A manifesto on explainability for artificial intelligence in medicine. Artif. Intell. Med. 133, 102423–102423 (2022)
Döhner, H., et al.: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453–474 (2010)
Döhner, H., et al.: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4), 424–447 (2017)
Döhner, H., et al.: Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12), 1345–1377 (2022)
Eisa, Y.A., et al.: The role of PHF6 in hematopoiesis and hematologic malignancies. Stem Cell Rev. Rep. 19(1), 67–75 (2023)
Estey, E.A.: Acute myeloid leukemia: 2019 update on risk-stratification and management. Am. J. Hematol. 93(10), 1267–1291 (2019)
Gal, O., et al.: Predicting complete remission of acute myeloid leukemia: machine learning applied to gene expression. Cancer Inf. 18, 1–5 (2019)
Grob, T., et al.: Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 139(15), 2347–2354 (2022)
Kastenhuber, E.R., Lowe, S.W.: Putting p53 in context. Cell 170(6), 1062–1078 (2017)
Kurzer, J.H., Weinberg, O.K.: PHF6 mutations in hematologic malignancies. Front. Oncol. 11, 704471–704471 (2021)
Lagunas-Rangel, F.A., et al.: Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int. J. Hematol. Oncol. Stem Cell Res. 11, 328–339 (2017)
Ley, T.J., et al.: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66–72 (2008)
Lin, W., et al.: Identification of MICALL2 as a novel prognostic biomarker correlating with inflammation and T cell exhaustion of kidney renal clear cell carcinoma. J. Cancer 13(4), 1214–1228 (2022)
Gerstung, M., et al.: Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat. Genet. 49, 332–340 (2017)
Mitchell, T.M.: Machine Learning. McGraw-Hill, New York (1997)
Mosquera Orgueira, A., et al.: Personalized survival prediction of patients with acute myeloblastic leukemia using gene expression profiling. Front. Oncol. 11, 657191–657191 (2021)
Nori, H., Caruana, R., Bu, Z., Shen, J.H., Kulkarni, J.: Accuracy, interpretability, and differential privacy via explainable boosting. In: Meila, M., Zhang, T. (eds.) Proceedings of the 38th International Conference on Machine Learning. Proceedings of Machine Learning Research, vol. 139, pp. 8227–8237. PMLR (2021)
Pelcovits, A., Niroula, R.: Acute myeloid leukemia: a review. R I Med. J. 103(3), 38–40 (2020)
Pimenta, R.J.G., et al.: Genome-wide approaches for the identification of markers and genes associated with sugarcane yellow leaf virus resistance. Sci. Rep. 11(1), 15730 (2021)
Rahman, M.M., et al.: Association of p53 gene mutation with helicobacter pylori infection in gastric cancer patients and its correlation with clinicopathological and environmental factors. World J. Oncol. 10(1), 46–54 (2019)
Sharon, D., et al.: DELE1 loss and dysfunctional integrated stress signaling in TP53 mutated AML is a novel pathway for venetoclax resistance [abstract]. Can. Res. 83, 2530 (2023)
The Cancer Genome Atlas Research Network: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368(22), 2059–2074 (2013)
Tibshirani, R.: Regression shrinkage and selection via the lasso. J. Royal Stat. Soc. Ser. B (Methodological) 58(1), 267–288 (1996)
Tyner, J.W., et al.: Functional genomic landscape of acute myeloid leukaemia. Nature 562(7728), 526–531 (2018)
Van Vlierberghe, P., et al.: PHF6 mutations in adult acute myeloid leukemia. Leukemia 25(1), 130–134 (2011)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Almeida, J.M., Castro, G.A., Machado-Neto, J.A., Almeida, T.A. (2023). An Explainable Model to Support the Decision About the Therapy Protocol for AML. In: Naldi, M.C., Bianchi, R.A.C. (eds) Intelligent Systems. BRACIS 2023. Lecture Notes in Computer Science(), vol 14195. Springer, Cham. https://doi.org/10.1007/978-3-031-45368-7_28
Download citation
DOI: https://doi.org/10.1007/978-3-031-45368-7_28
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-45367-0
Online ISBN: 978-3-031-45368-7
eBook Packages: Computer ScienceComputer Science (R0)